Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Calmare Therapeutics Inc. (CTTC)

Add CTTC Price Alert      Hide Sticky   Hide Intro
Moderator: conix, mog1962
Search This Board: 
Last Post: 12/7/2017 9:23:00 AM - Followers: 36 - Board type: Free - Posts Today: 0



Calmare Therapuetics Incorporated.,  (OTCQX: CTTC)

MAYO CLINIC News on Calmare (November, 2014)  




Only machine of its kind in SC appears to get results for patients in pain

Helen Adams | | May 18, 2017


Retired teacher Douglas Foxworth was suffering from pain so severe that it felt like his feet were on fire. The cause was unknown — it’s called idiopathic peripheral neuropathy. When the Sumter man heard about a new pain treatment at MUSC Health called scrambler therapy, he jumped at the chance to try it.

“That morning when I went in, I was practically in tears. When they asked how my pain was, I said a nine, pushing a ‘ten’ out of ten,” Foxworth said.

He became one of the first patients in South Carolina to try scrambler therapy. The scrambler device, by Calmare, has been cleared by the Food and Drug Administration. Nurse Julie Watson described how it works. “The scrambler therapy device uses transcutaneous electrical stimulation to replace maladaptive pain information with ‘non-painful’ or ‘normal’ messages. It does this by traveling along the same pathways to the brain.” 

In other words, as its name suggests, scrambler uses electrical stimulation on the skin to scramble what nerves are trying to tell the brain. Each treatment lasts between a half-hour and 45 minutes. Foxworth had 12 sessions over a 2 1/2-week period. “The first day when they put those electrodes on, about 10 or 15 minutes after, the pain level went down,” he said. “It didn’t last, but the pain level went down to where it was tolerable.”

By the end of the 12th session, the difference was dramatic. “I still have some pain, but I’m no longer on pain medication. The pain is very mild,” Foxworth said. “I consider that this was effective to eliminate probably 90 percent of my pain.”

Palliative care specialist Pat Coyne, who introduced scrambler therapy at MUSC Health, said about 80 percent of the patients who try it feel a substantial difference. He first heard about scrambler therapy while he was working at Virginia Commonwealth University. “We did three research studies,” he said. “We went into the research trying to prove it didn’t work, and everyone kept saying they felt better.”

The skepticism Coyne initially felt resonates with MUSC Health palliative care doctor John Gibson. “Our team has been very happy with the results we have seen,” Gibson said. “I think the biggest point of skepticism for everyone who sees scrambler is that no one really understands how it works. There are theories that make sense, but no one has proven how it works.”

Scrambler therapy was invented by an Italian professor, Coyne said. It has been around for almost two decades, but wasn’t introduced in the U.S. until around 2010. The device requires careful monitoring. “With the electrodes, it senses the nerve firing. The electricity comes in wave forms and pulses. You adjust those based on when the patient tells you the pain is going away,” Coyne said. 

His research team wasn’t alone in finding scrambler therapy was effective. An article in the journal Supportive Care in Cancer said 19 out of 20 reports on scrambler therapy came up with positive results.

It’s a nuanced treatment, Coyne said. “A nurse is going to be sitting at the bedside and adjusting the dials. It will be different each time, and the leads will change because the pain typically gets smaller with each treatment. Really, what it’s trying to do is, when the nerves fire, it’s firing against them. So the pulsation never makes it to the brain and you don’t feel pain. And in doing so, we know it changes the way calcium is absorbed. Nerves that fire a lot actually are sometimes calcium deprived. You’re trying to reset the nerves to normal.”

Coyne said research shows patients who had scrambler therapy showed improvements in their natural pain-fighting reserves. “They get depleted when they’re fighting pain all the time. We found their endorphins changed.”

During a training period at MUSC Health, patients could volunteer to try scrambler therapy. It’s now in use in MUSC Hollings Cancer Center, covered by Medicare, Medicaid, and some insurance providers. “Starting off, we’re going to focus on the cancer population, but it’s going to be open to anyone who has this nerve pain,” Coyne said.

Watson, who has treated patients with the scrambler, said cancer treatments can cause neuropathic pain and sensation problems. “They may be able to stay on their treatments longer or at doses they may not have been able to previously tolerate. This treatment can be life-changing for some by enhancing quality of life and allowing them to do activities they may not have previously been able to do,” Watson said. 

“We treated a patient with chemo-induced neuropathy, and he wanted to work out and jump rope as he once did. Before he completed his treatments, his numbness had improved so much in his feet that he began jumping rope, which he had not been able to do for several years. Having a non-invasive, non-pharmacological alternative such as scrambler therapy that has shown proven benefit for neuropathic pain is a tremendous stride here at MUSC Health.”

Gibson, the palliative care physician, said it’s important to look for new ways of treating pain. “Unfortunately, and despite years of effort, the health system does not do a great job of treating pain, particularly neuropathic pain, which is really what scrambler is targeted toward,” he said.

“The mainstay of treatment currently is drugs, all of which come with a number of side effects. In many instances, these medicines do not adequately control the pain or cannot be tolerated by the patient. Among these medications are the opioids, which pose possible risks to the patient, and as everyone now has seen commonly on the news, opioids come with a heavy burden on our public health," Gibson said.

Neuropathic pain, particularly chemotherapy-induced neuropathy, is typically a chronic form of pain. "There is very little evidence that opioids are effective in chronic pain, and there are significant issues with tolerance to these medicines which often leads patients to higher and higher doses of the medicine, usually with more side effects," Gibson said. "Scrambler offers the potential to significantly reduce the patient’s pain with basically no side effects and no ongoing need to take pills. Without the pills, many of the societal burdens of pain medicines will be reduced as well.”

Coyne envisions having several scrambler devices at MUSC Health in the future. With scrambler therapy, he said, “The numbness goes away, which no one’s ever found a way to fix. Some meds take away the pain, but the numbness stays.”

To be treated with scrambler therapy at MUSC Health, patients must have a referral from a doctor. Watson said common conditions treated include chemo-induced neuropathy, diabetic neuropathy, phantom limb pain, failed back syndrome, trigeminal neuralgia, postherpetic neuralgia and chronic regional pain syndrome.

Before scrambler therapy, Foxworth, the teacher from Sumter, was taking the pain reliever gabapentin. He’s not anymore, but knows his pain may flare up again. “More than likely it will reoccur. When that happens, I’ll go back for what they call a booster treatment. I’m very pleased with what scrambler therapy has done for me."]b\[


Berkeley, California Neurology Practice Adds Calmare(R) Pain Management Therapy

Dr. Selena Ellis to Treat Chronic Neuropathic Pain with Non-Invasive and Non-Addictive Technology

BERKELEY, CA - (NewMediaWire) - June 13, 2017 - Dr. Selena Ellis ( is proud to announce her medical practice will be the first neurology practice in the western United States to offer Calmare® therapy, an effective non-opioid treatment for neuropathic pain. Dr. Ellis's medical practice treats chronic pain in patients suffering from trigeminal neuralgia, peripheral neuropathy, complex regional pain syndrome (CRPS), headaches and migraines. After an in-depth evaluation process which included the successful treatment of her patients with chronic neuropathic pain, Dr. Ellis has recently added this very promising therapy, also known as "Scrambler Therapy".

Calmare® is a FDA-cleared device that provides a non-invasive therapy for the treatment of chronic neuropathic pain. Calmare® therapy has also been successful in achieving chronic pain relief for patients suffering from failed surgical back syndrome and multiple neuropathies including chemotherapy-induced peripheral neuropathy (CIPN).

Significantly, there have been no reports of adverse side effects associated with this therapeutic modality.

The Calmare® technology employs electrostimulation with a low electrical current directed at the central nervous system and delivered through applied electrodes on the patient's skin surrounding the pain area. Sixteen electrical impulse algorithms are programmed to specifically target the body's sensory fiber pathway (which transmits slower and chronic pain signals). These electrical signals help "re-program" the brain's receipt of the pain signal. In many patients, these signals provide longer-lasting pain relief than those that "blocking" the pain signal, such as with transcutaneous electrical nerve stimulation (TENS).


Physicians using Calmare therapy have reported that patients who experience a reduction in pain after their first 45-minute treatment have a high probability of experiencing a significant reduction in chronic pain after completing a ten-treatment regimen. Patients should be weaned off certain medications before starting the therapy to achieve the best result.

Dr. Ellis says, "My practice focuses on providing chronic pain relief to my patients using the most safe, effective and non-addictive therapies available. As a neurologist, I am open to new modalities after conducting a complete evaluation of the patient. After I saw the positive results in some of my patients after using Calmare, I knew I wanted to be the first neurologist to offer the technology in the western US."

About Selena Ellis, MD (

Dr. Ellis attended medical school at the University of Washington in Seattle and completed her neurology residency at the UCLA School of Medicine in 2002. She obtained subspecialty training in electrodiagnosis of neuromuscular disease as Chief Resident and Fellow at the Wadsworth VA/UCLA Department of Neurology.

Dr. Ellis is board-certified in general neurology and electrodiagnostic medicine by the American Board of Psychiatry and Neurology (ABPN) and the American Board of Electrodiagnostic Medicine (AANEM). She was the president and longtime board member of the San Francisco Neurological Society Dr. Ellis had the first medical practice in Northern California with an AANEM-certified electromyogram (EMG) lab, in addition to being the first neurologist in the western US to offer Calmare therapy.

Dr. Ellis treats common neurological disorders such as headache, peripheral neuropathy, trigeminal neuralgia, occipital neuralgia, complex regional pain syndrome, back pain, and sciatica. Other common symptoms treated at her practice include pain syndromes of many types, difficulty with gait or balance, and sensory changes to the arms or legs. Dr. Ellis also has subspecialty training in evaluation and management of problems affecting the peripheral nervous system, including systemic neuropathies, mononeuropathy and radiculopathy.

About Calmare/Scrambler Therapy

Distributed by Competitive Technologies, Inc., the Calmare® (also known as Scrambler therapy) is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive and non-narcotic treatment of chronic neuropathic and oncologic pain. Using a biophysical rather than a biochemical approach, Calmare employs a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin surrounding the area in pain. The device creates and relays a non-pain signal which becomes the dominant signal received by the brain and overrides the pain signal to provide relief for the patient. The Calmare device has been used to successfully treat over 10,000 chronic pain patients worldwide. 


Cynthia Laird at 510-644-2282 for Dr. Selena Ellis or


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTTC News: Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) 12/08/2017 04:28:16 PM
CTTC News: Proxy Statment - Contested Solicitations (definitive) (defc14a) 12/05/2017 11:00:10 AM
CTTC News: Proxy Statement - Contested Solicitations (preliminary) (prec14a) 12/04/2017 03:06:51 PM
CTTC News: Proxy Statements Not Involving Contested Solicitations (preliminary) (pren14a) 11/22/2017 04:44:13 PM
CTTC News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/15/2017 05:16:35 PM
#14616   Mercy! Where is everyone? Has the board been nobodysbusiness 12/07/17 09:22:59 AM
#14615   New proxy statement makes for entertaining reading: nobodysbusiness 12/05/17 10:55:51 AM
#14614   If you're so excited about the technology then nobodysbusiness 11/28/17 09:51:42 AM
#14613   "They do research" and THEN they decide NOT nobodysbusiness 11/28/17 09:47:08 AM
#14612   Maybe you could shed some light on who powderbum 11/28/17 12:58:31 AM
#14611   That's right Powderbutt. JHMC & MC do Deceived 11/27/17 10:08:20 PM
#14610   Speak for yourself. Any organization that uses the Munchqin 11/27/17 10:06:54 PM
#14609   Nobody cares. They do research. powderbum 11/27/17 09:13:58 PM
#14608   Lewis lawsuit update: nobodysbusiness 11/27/17 07:42:59 PM
#14607   And tell us all AGAIN just how MANY nobodysbusiness 11/27/17 07:40:37 PM
#14606   Why? because your comment about a quack device powderbum 11/25/17 11:31:43 AM
#14605   You should ask them! For me, I see Munchqin 11/25/17 01:23:25 AM
#14604   My question is WHY? Why are these people nobodysbusiness 11/24/17 06:25:28 PM
#14603   The proposals are good and the I think Munchqin 11/24/17 12:28:40 PM
#14602 andy55q 11/24/17 10:40:14 AM
#14601   Opioids: 500 billion dollar problem. powderbum 11/20/17 03:08:40 AM
#14600   Very true! Because CTTC currently have no rights Munchqin 11/19/17 12:55:19 AM
#14599   I think it's interesting that in the article Deceived 11/17/17 09:43:29 PM
#14598   GEOMC lawsuit update: nobodysbusiness 11/17/17 06:44:30 PM
#14597   And tell us again WHICH of the author's nobodysbusiness 11/17/17 06:41:46 PM
#14596   Does Calmare really work? powderbum 11/17/17 10:09:15 AM
#14595   I will guarantee the 200 share downtick today powderbum 11/14/17 11:29:54 AM
#14594   Nobody sells 100 shares of a .07 stock. powderbum 11/14/17 11:14:41 AM
#14593   Where is everyone? Did you know CTTC stocks Munchqin 11/13/17 09:35:07 PM
#14592   Actually you should be asking whether they DON'T nobodysbusiness 11/10/17 09:10:15 AM
#14591   Indications that soon the shares will have 0 Munchqin 11/09/17 08:56:15 PM
#14590   WOW!!!!!! Now the share price is dropping on big mog1962 11/09/17 06:36:31 PM
#14589   I'd like to ask "Dr. Tom Smith" why nobodysbusiness 11/06/17 10:54:54 PM
#14588   I don't expect it to be published ever. Munchqin 11/06/17 05:13:55 PM
#14587   You would have to talk to Dr. Tom powderbum 11/06/17 12:07:24 PM
#14586   what were the results? why aren't published yet? Munchqin 11/05/17 09:43:27 PM
#14585   'Wrong again'? yep, you are wrong again and Munchqin 11/05/17 03:20:02 PM
#14584   Wrong again. This study was paid for by powderbum 11/04/17 06:26:11 PM
#14583   'The fact they want to do another study Munchqin 11/03/17 08:59:53 PM
#14582   How do you know what the results were? powderbum 11/03/17 06:19:25 PM
#14581   That is strange! They don't have good results Munchqin 11/03/17 05:52:58 PM
#14580   Not a great article since it covers a mog1962 11/03/17 12:41:03 PM
#14579   CTTC is a bit of a rag company conix 11/03/17 10:25:20 AM
#14578   ROFLMAO! "Participants "must have a life expectancy > nobodysbusiness 11/02/17 11:56:03 PM
#14577   Johns Hopkins starts New cancer study with Calmare : powderbum 11/02/17 06:09:45 PM
#14576   Great Article mentions Calmare as an alternative to opioids. powderbum 11/02/17 05:28:11 PM
#14575   LOL! I didn't notice that! nobodysbusiness 11/02/17 12:29:38 PM
#14574   after you click to that web site for mog1962 11/02/17 10:10:07 AM
#14573   This is a good one -- CTTC has nobodysbusiness 11/02/17 10:02:31 AM
#14572   Even I must agree with powderbum about the mog1962 11/01/17 03:04:04 PM
#14571   Well I'm not guessing I know you are powderbum 11/01/17 11:20:40 AM
#14570   That reminds me -- anyone ever figure out nobodysbusiness 11/01/17 10:52:42 AM
#14569   Relive the the lies of CM (2016) Munchqin 10/31/17 09:53:51 PM
#14568   The problem is the Military doesn't buy Calmare Munchqin 10/31/17 09:47:12 PM
#14567   The military is having great success with Calmare. powderbum 10/31/17 05:24:37 PM